Cargando…
REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients
OBJECTIVES: This double-blind randomized controlled trial investigated raising serum 25-hydroxyvitamin D (25D) with extended-release calcifediol (ERC) on time to symptom resolution in patients with mild to moderate COVID-19. METHODS: COVID-19 outpatients received oral ERC (300 mcg on days 1–3 and 60...
Autores principales: | Bishop, Charles W., Ashfaq, Akhtar, Melnick, Joel Z., Vazquez-Escarpanter, Enrique, Fialkow, Jonathan A., Strugnell, Stephen A., Choe, John, Kalantar-Zadeh, Kamyar, Federman, Noah C., Ng, David, Adams, John S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OPKO Health. Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639413/ https://www.ncbi.nlm.nih.gov/pubmed/36529089 http://dx.doi.org/10.1016/j.nut.2022.111899 |
Ejemplares similares
-
LBSAT230 Daily Variation In Serum Calcifediol In Japanese And Non-japanese Adults
por: Ashfaq, Akhtar, et al.
Publicado: (2022) -
LBSAT229 Extended-release Calcifediol Effectively Raised 25-hydroxyvitamin D In CKD Despite Obesity
por: Strugnell, Stephen A, et al.
Publicado: (2022) -
LBSAT131 Extended-release Calcifediol Reduced Ipth And Normalized 1,25-dihydroxyvitamin D In Esrd.
por: Ashfaq, Akhtar, et al.
Publicado: (2022) -
Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism
por: Bishop, Charles W., et al.
Publicado: (2022) -
Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
por: Germain, Michael J., et al.
Publicado: (2022)